GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Theralase Technologies Inc (TSXV:TLT) » Definitions » Total Assets

Theralase Technologies (TSXV:TLT) Total Assets : C$3.25 Mil (As of Dec. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Theralase Technologies Total Assets?

Theralase Technologies's Total Assets for the quarter that ended in Dec. 2024 was C$3.25 Mil.

During the past 12 months, Theralase Technologies's average Total Assets Growth Rate was -7.90% per year. During the past 3 years, the average Total Assets Growth Rate was 9.70% per year. During the past 5 years, the average Total Assets Growth Rate was 4.40% per year. During the past 10 years, the average Total Assets Growth Rate was 1.40% per year.

During the past 13 years, Theralase Technologies's highest 3-Year average Total Assets Growth Rate was 1376.40%. The lowest was -28.20%. And the median was -0.90%.

Total Assets is connected with ROA %. Theralase Technologies's annualized ROA % for the quarter that ended in Dec. 2024 was -113.53%. Total Assets is also linked to Revenue through Asset Turnover. Theralase Technologies's Asset Turnover for the quarter that ended in Dec. 2024 was 0.13.


Theralase Technologies Total Assets Historical Data

The historical data trend for Theralase Technologies's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Theralase Technologies Total Assets Chart

Theralase Technologies Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.02 5.95 4.16 3.28 3.25

Theralase Technologies Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.28 3.25 3.39 3.22 3.25

Theralase Technologies Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Theralase Technologies's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (A: Dec. 2024 )+Total Liabilities (A: Dec. 2024 )
=2.067+1.18
=3.25

Theralase Technologies's Total Assets for the quarter that ended in Dec. 2024 is calculated as

Total Assets=Total Equity (Q: Dec. 2024 )+Total Liabilities (Q: Dec. 2024 )
=2.067+1.18
=3.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Theralase Technologies  (TSXV:TLT) Total Assets Explanation

Total Assets is connected with ROA %.

Theralase Technologies's annualized ROA % for the quarter that ended in Dec. 2024 is

ROA %=Net Income (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=-3.672/( (3.222+3.247)/ 2 )
=-3.672/3.2345
=-113.53 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Theralase Technologies's Asset Turnover for the quarter that ended in Dec. 2024 is

Asset Turnover
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0.41/( (3.222+3.247)/ 2 )
=0.41/3.2345
=0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Theralase Technologies Total Assets Related Terms

Thank you for viewing the detailed overview of Theralase Technologies's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Theralase Technologies Business Description

Traded in Other Exchanges
Address
41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc is a clinical-stage pharmaceutical company. It is dedicated to the research and development of light-activated Photo Dynamic Compounds, their associated drug formulations, and technology platforms intended to safely and effectively; treat various cancers, bacteria, and viruses. The Cool Laser Technology division designs, develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the FDA for the healing of chronic knee pain and when used off-label for healing numerous nerve, muscle, and joint conditions. The ACT division conducts preclinical and clinical research and development for PDCs, in the treatment of cancer, with assistance from the CLT division to develop medical lasers to activate them.
Executives
Matthew Thomas Perraton Director
Roger John Dumoulin-white 10% Security Holder, Director, Senior Officer
Kristina Maria Hachey Senior Officer
Arkady Mandel Senior Officer
Guy John Anderson Director
Shawn Shirazi Senior Officer

Theralase Technologies Headlines

From GuruFocus

Top 5 4th Quarter Trades of ONE PLUS ONE WEALTH MANAGEMENT, LLC

By GuruFocus Research GuruFocus Editor 01-19-2023

Louis Moore Bacon Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 11-14-2022

Top 5 3rd Quarter Trades of Strong Tower Advisory Services

By GuruFocus Research GuruFocus Editor 10-15-2022

Top 5 4th Quarter Trades of VANTAGEPOINT INVESTMENT ADVISERS LLC

By GuruFocus Research GuruFocus Editor 01-21-2023

Top 5 2nd Quarter Trades of Louis Moore Bacon

By GuruFocus Research GuruFocus Editor 08-15-2022

Top 5 2nd Quarter Trades of SYNOVUS FINANCIAL CORP

By GuruFocus Research GuruFocus Editor 08-11-2022

Rafferty Asset Management, LLC's Top 5 Buys of the 4th Quarter

By GuruFocus Research GuruFocus Editor 02-15-2023

Top 5 4th Quarter Trades of Starfox Financial Services, LLC

By GuruFocus Research GuruFocus Editor 02-08-2023

Top 5 2nd Quarter Trades of Pinnacle Wealth Management, LLC

By GuruFocus Research GuruFocus Editor 07-29-2022